159 related articles for article (PubMed ID: 24393663)
1. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor.
Hansen L; Petersen LC; Lauritzen B; Clausen JT; Grell SN; Agersø H; Sørensen BB; Hilden I; Almholt K
Thromb Res; 2014 Mar; 133(3):464-71. PubMed ID: 24393663
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration.
Agersø H; Overgaard RV; Petersen MB; Hansen L; Hermit MB; Sørensen MH; Petersen LC; Hilden I
Eur J Pharm Sci; 2014 Jun; 56():65-9. PubMed ID: 24568891
[TBL] [Abstract][Full Text] [Related]
3. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies.
Yuan D; Rode F; Cao Y
Eur J Pharm Sci; 2019 Oct; 138():105032. PubMed ID: 31394258
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab.
Chowdary P
Drugs; 2018 Jun; 78(9):881-890. PubMed ID: 29845491
[TBL] [Abstract][Full Text] [Related]
5. Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data.
Eichler H; Angchaisuksiri P; Kavakli K; Knoebl P; Windyga J; Jiménez-Yuste V; Harder Delff P; Chowdary P
Haemophilia; 2019 Jan; 25(1):60-66. PubMed ID: 30408848
[TBL] [Abstract][Full Text] [Related]
6. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model.
Hilden I; Lauritzen B; Sørensen BB; Clausen JT; Jespersgaard C; Krogh BO; Bowler AN; Breinholt J; Gruhler A; Svensson LA; Petersen HH; Petersen LC; Balling KW; Hansen L; Hermit MB; Egebjerg T; Friederichsen B; Ezban M; Bjørn SE
Blood; 2012 Jun; 119(24):5871-8. PubMed ID: 22563084
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
[TBL] [Abstract][Full Text] [Related]
8. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma.
Abumiya T; Enjyoji K; Kokawa T; Kamikubo Y; Kato H
J Biochem; 1995 Jul; 118(1):178-82. PubMed ID: 8537308
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A.
Eichler H; Angchaisuksiri P; Kavakli K; Knoebl P; Windyga J; Jiménez-Yuste V; Hyseni A; Friedrich U; Chowdary P
J Thromb Haemost; 2018 Nov; 16(11):2184-2195. PubMed ID: 30137664
[TBL] [Abstract][Full Text] [Related]
10. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.
Chowdary P
Int J Hematol; 2020 Jan; 111(1):42-50. PubMed ID: 30302740
[TBL] [Abstract][Full Text] [Related]
11. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay.
Waters EK; Sigh J; Friedrich U; Hilden I; Sørensen BB
Haemophilia; 2017 Sep; 23(5):769-776. PubMed ID: 28594458
[TBL] [Abstract][Full Text] [Related]
12. Concizumab: a novel anti-TFPI therapeutic for hemophilia.
Shapiro AD
Blood Adv; 2021 Jan; 5(1):279. PubMed ID: 33570646
[TBL] [Abstract][Full Text] [Related]
13. Hemostatic properties of a TFPI antibody.
Petersen LC
Thromb Res; 2012 May; 129 Suppl 2():S44-5. PubMed ID: 22405586
[TBL] [Abstract][Full Text] [Related]
14. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.
Chowdary P; Lethagen S; Friedrich U; Brand B; Hay C; Abdul Karim F; Klamroth R; Knoebl P; Laffan M; Mahlangu J; Miesbach W; Dalsgaard Nielsen J; Martín-Salces M; Angchaisuksiri P
J Thromb Haemost; 2015 May; 13(5):743-54. PubMed ID: 25641556
[TBL] [Abstract][Full Text] [Related]
15. Concizumab: First Approval.
Keam SJ
Drugs; 2023 Jul; 83(11):1053-1059. PubMed ID: 37341887
[TBL] [Abstract][Full Text] [Related]
16. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
[TBL] [Abstract][Full Text] [Related]
17. Role for the Kunitz-3 domain of tissue factor pathway inhibitor-alpha in cell surface binding.
Piro O; Broze GJ
Circulation; 2004 Dec; 110(23):3567-72. PubMed ID: 15557366
[TBL] [Abstract][Full Text] [Related]
18. Activity of secreted Kunitz domain 1 variants of tissue factor pathway inhibitor.
Johnson K; Zaror I; Bauer D; Choi Y; Creasey A; Innis M
Thromb Haemost; 1998 Oct; 80(4):585-7. PubMed ID: 9798974
[TBL] [Abstract][Full Text] [Related]
19. Tissue factor pathway inhibitor binds to platelet thrombospondin-1.
Mast AE; Stadanlick JE; Lockett JM; Dietzen DJ; Hasty KA; Hall CL
J Biol Chem; 2000 Oct; 275(41):31715-21. PubMed ID: 10922378
[TBL] [Abstract][Full Text] [Related]
20. Purification of tissue factor pathway inhibitor (TFPI) from rabbit plasma and characterization of its differences from TFPI isolated from human plasma.
Warn-Cramer BJ; Maki SL
Thromb Res; 1992 Aug; 67(4):367-83. PubMed ID: 1412217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
